Wednesday 30 th March
GP VTS
What to consider with contraception
Pills
IUD/IUS
Implants and injection
Special circumstances
QOF
Case studies
Surgical methods - no funding
Natural methods
Gillick (in too much detail)
Infertility
Common consultation
Increased choice
Benefits and risks
Unwanted pregnancy
Personal preference
Lifestyle
Medical history
Family history
Risk of STI
Confirm not pregnant
Previous methods
Current medical problems
BP
Migraine?
Smoker?
Family history of cancers
Vary by oestrogen content
Vary by progesterone type
21 pills then break
Aged 35y + smoker
>50y
HTN
IHD/CVA/PVD
DM
VTE
Focal migraine
Female malignancy
Hormonal problems in pregnancy
Breast feeding
Acute hepatitis
Porphyria
Microgynon 30
Ovranette
150mcg - levonorgesterol (progesterone)
30mcg – ethinylestradiol (oestrogen)
£2.99
£2.29
Acne
Headache
Depression
Weight gain
Breast symptoms
Decreased libido
Desogesterel – Marvelon
Gestodene – Femodene
Norgestimate – Cilest
Drospirenone - Yasmin
£6.70
£7.18
£11.94
£14.70
Cyproterone acetate – Dianette
£3.70
Not licensed for contraception alone
Used in treatment of acne
Breast tenderness
Nausea
Weight gain
Bloating
Loestrin 20 – 20mcg ethinylestradiol
£2.70
First few months
Exclude other cause
Compliance
New advice on antibiotics
Enzyme inducers
Affect all hormonal contraception
Current advice
Take ASAP
2 or less
3 or more
Older women
Smokers
VTE history
HTN, DM, Migraine
Breastfeeding <6m post-partum
Cerazette- desogesterel - £8.85
Micronor/Noriday – norethisterone - £2.00
Femulen – etynodiol - £3.31
Norgeston – levonorgesterel - £0.98
Start on day 1 of cycle
Take every day – no breaks
Missed pill
D+V
Higher failure rate
Irregular bleeding
Risk of ectopic
LARC 23% of primary methods of contraception
LARC methods
intrauterine devices [IUDs]
the intrauterine system [IUS] injectable contraceptives
implants
all LARCs more cost effective than the COCP even at
1 year of use
IUDs, the IUS and implants are more cost effective than the injectable contraceptives (DMPA)
All LARC methods are suitable for:
nulliparous women
breastfeeding
women who have had an abortion
BMI > 30
women with HIV – encourage safer sex
women with diabetes
women with migraine with or without aura – all progestogen-only methods may be used
women with contraindication to oestrogen
contraceptive efficacy
duration of use
risks and possible side effects
non-contraceptive benefits
initiation and removal/discontinuation
when to seek help while using the method.
Copper IUDs IUS (Mirena) Progestogen-only injections
Unacceptable vaginal bleeding/pain
Ectopic pregnancy
1/20 (lower than without contraception)
Unacceptable vaginal bleeding/pain
Ectopic pregnancy
1/20
Altered bleeding pattern eg. persistent
Small loss in bone mineral density, largely recovered when stopped.
Implants
Irregular bleeding
Acne
PID <1% low risk women
PID <1% Weight gain – up to 2-3kg over a year
Uterine perforation
<1/1000
Uterine perforation
<1/1000
No evidence of effect on depression, acne or headaches
No evidence of effect on weight, mood, libido, headaches, BMD
Mood/libido change
No weight gain
Mood/libido change, acne
No weight gain
Progestogen-only implants/DMPA may improve dysmenorrhoea and the symptoms of endometriosis.
Up to 20% of women using a progestogenonly implant will be amenorrhoeic
A RTC found a significant reduction in dysmenorrhoea and menorrhagia with the
LNG-IUS (Mirena) when compared to a Cu-
IUD.
Implanon/Nexplanon
Nexplanon® is a progestogen-only subdermal implant ( non palpable ) - now replaced Implanon®.
Nexplanon and Implanon are bioequivalent (i.e. they both contain 68 mg etonogestrel and they have the same release rate and 3-year duration of action).
Nexplanon is radio-opaque and has a different application device and insertion technique.
When fitting:
Check the woman is not pregnant!
Nexplanon may be inserted:
at any time
(but use barrier methods for first 7 days if the woman is amenorrhoeic or it is more than 5 days since menstrual bleeding started)
Prevention of ovulation.
3 years
No delay
20% of users - no bleeding
50% will have infrequent, frequent or prolonged bleeding
Bleeding patterns are likely to remain irregular.
Not recommended for women taking enzymeinducing drugs eg. Anti-epileptics, St.Johns Wort.
Useful if high BMI
Copper devices or Mirena coil.
Test for:
Chlamydia trachomatis in women at risk of
STIs
Neisseria gonorrhoeae in women at risk of
STIs in areas where it is prevalent
For woman at increased risk of STIs, give prophylactic antibiotics before inserting an
IUD or IUS if testing has not been completed.
Like the implant - an IUD or IUS may be inserted:
at any time
If the woman has epilepsy, seizure risk may be increased at the time of fitting an IUD or
IUS.
Women with a history of venous thromboembolism (VTE) may use the IUS.
Pelvic infection risk - 20 days following insertion
risk same as non-IUD-using population thereafter
Irregular bleeding common in the first 6 months after insertion of the LNG-IUS but by 1 year amenorrhoea or light bleeding is usual.
Previous endocarditis
Prosthetic heart valve
require intravenous antibiotic prophylaxis
Copper is toxic to ovum and sperm inhibiting fertilisation.
In addition, the endometrial inflammatory reaction has an antiimplantation effect and alterations in the copper content of cervical mucus inhibit sperm penetration.
A Cu-IUD inserted when a woman >40 years can be retained until the menopause is confirmed.
>50yrs - 1 year after the last menstrual period
<50yrs - 2 years
Copper IUDs - 5-10 years
Prevents implantation.
Effects on cervical mucus reduce sperm penetration.
Inserted >45 years and amenorrhoeic - may retain the LNG-IUS until the menopause.
Randomised trials show that the LNG-IUS provides effective contraception for up to 7 years – licensed for 5 years .
At first follow-up visit (after the first menses, or 3–6 weeks after insertion)
exclude infection, perforation or expulsion.
IUD only: For heavier and/or prolonged bleeding associated with use of an IUD:
– treat with NSAIDs and tranexamic acid
– or suggest changing to the IUS if the woman finds bleeding unacceptable.
Depo Provera
Depo Provera or Noristerat (short term use)
Inhibits ovulation.
Check not pregnant!
Can give:
– up to 5 th day of the menstrual cycle without the need for additional contraceptives
– or use barrier contraception 7 days
Every 12 weeks
Deep intramuscular injection
into the gluteal or deltoid muscle or the lateral thigh
Delay up to 1 year in the return of fertility BUT
…no evidence of reduced fertility long term
Amenorrhoea (14.4%)
Infrequent bleeding (24.2%)
Spotting (27.9%)
Prolonged bleeding (33.5%) were all reported
Small loss of BMD, which is usually recovered after discontinuation.
Women should be advised that there is no available evidence on the effect of DMPA on longterm fracture risk.
Use may continue to age 50 years.
Can try:
3 cycles of 20-30mcg COC, taken cyclically
– can be repeated
If COC contraindicated: mefenamic acid
500mg BD until bleeding settles…
Cerazette 1 tab daily for approx. 3 months
Repeat injections may be given up to 2 weeks late.
DMPA use >2 years, review and discuss the balance of benefits and risks again eg. BMD
No evidence of congenital malformation to the fetus if pregnancy occurs during DMPA use.
Good choice if on enzyme-inducing drugs
Routine follow-up
IUD/IUS
At 3–6 weeks
Return if problems or time for removal.
Injectable contraceptives
Every 12 weeks; every 8 weeks for NET-EN
Implants
No routine follow-up
Under 16s and post-partum
Fraser Guidelines and Gillick Competence
Be aware of the law
Duty of care and a duty of confidentiality to all patients, including under 16s.
> 25% of young people are sexually active
<16 years.
Least likely to use contraception.
Confidentiality
If considering any disclosure of information
- weigh up a right to privacy against:
current or likely harm
what any such disclosure is intended to achieve
potential benefits to the young person’s well-being.
Except in the most exceptional of circumstances consult the young person and offer to support a voluntary disclosure.
the young person understands the health professional’s advice;
cannot persuade the young person to inform his or her parents or allow the doctor to inform the parents that he or she is seeking contraceptive advice;
the young person is very likely to begin or continue having intercourse with or without contraceptive treatment;
unless he or she receives contraceptive advice or treatment, the young person’s physical or mental health or both are likely to suffer;
the young person’s best interests require the health professional to give contraceptive advice, treatment or both without parental consent .
The Act states that, a person is not guilty of aiding, abetting or counselling a sexual offence against a child where they are acting for the purpose of:
protecting a child from pregnancy or STIs
protecting the physical safety of a child,
promoting a child’s emotional well-being by the giving of advice.
Choices for women post-partum, including breastfeeding
IUD – copper: from 4 weeks after childbirth
IUS - Mirena: from 4 weeks after childbirth
DMPA injection: any time after childbirth, if
>21 days need additional.
Implants - Nexplanon: any time after childbirth; if >21 days postpartum need additional
Progestogen-only injectable contraception or implant is appropriate:
after surgical abortion
(second part of) medical abortion
miscarriage.
If DMPA or Nexplanon within 5 days
Ideally insert IUD or IUS within the first 48 hours or delay until 4 weeks postpartum.
Less than 72 hours – levenorgesterol - 1.5mg
Between 72h and 120h – EllaOne
Most effective is Copper IUD
Advise to return if abdominal pain or next period overdue
Advice on STI
Plan contraceptive follow up
Less than 24w
Reasons
Medical and surgical
Marie Stopes centres
http://www.mariestopes.org.uk
LARC – offered and coded
Chlamydia testing – people under 25
17y
Only current partner
BMI 22
Non-smoker
Wants contraception
Comes back 3m later
Spots over face, some on back
42y
Finished family
Wants something long term
24y
New baby
Unplanned pregnancy
37y
Heavy smoker
BMI 42
Bed bound
Diabetic
Previous DVT
BP 172/104
Faculty of Family Planning
Oxford handbook of General Practice
BNF
Marie Stopes
Monkgate Clinic